Intralesional BO-112 Shows Promise as Nonsurgical Approach for High-Risk BCC
Phase 2b clinical trial results for the intralesional therapy BO-112 show promise as a nonsurgical treatment for basal cell carcinoma. The study suggests the therapy could be particularly effective for tumors in sensitive cosmetic areas like the head and neck.
Why it matters
Advancements in nonsurgical cancer treatments can significantly improve patient quality of life by reducing the need for invasive procedures in visible areas.
Intralesional BO-112 demonstrated promising clinical and pathological responses in patients with resectable basal cell carcinoma (BCC), including patients with high-risk tumors of the head and neck, according to phase 2b results presented at the 2026 European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria.1
The findings from the multicenter, single-arm SPOTLIGHT-204 trial (NCT06422936) suggest that the investigational therapy could eventually offer a nonsurgical treatment option for selected patients with BCC, particularly when tumors occur in cosmetically or functionally sensitive areas.
In an interview with Dermatology Times, Josep Malvehy, MD, PhD, professor at the University of Barcelona and director of the Skin Cancer Program in the Dermatology Department at Hospital Clínic of Barcelona, highlighted the potential implications of reducing or avoiding surgery in this population.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in